Treatment outcome and clinical characteristics of HER2 mutated advanced non‐small cell lung cancer patients in China

Cancer statistics, 2019

(2019) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Afatinib in non-small cell lung cancer with HER2 mutations: results of the prospective, open-label phase II NICHE trial of European Thoracic Oncology Platform (ETOP)

(2019) Rafal Dziadziuszko et al.   Journal of Thoracic Oncology

Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study

(2019) W. Victoria Lai et al.   EUROPEAN JOURNAL OF CANCER

Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers

(2018) Yan Wang et al.   BMC CANCER

TargetingHER2Aberrations in Non–Small Cell Lung Cancer with Osimertinib

(2018) Shengwu Liu et al.   CLINICAL CANCER RESEARCH

Clinical Activity of Pan- HER Inhibitors Against HER2 -Mutant Lung Adenocarcinoma

(2018) In-Jae Oh et al.   Clinical Lung Cancer

Global named patient use program of afatinib in advanced non-small-cell lung carcinoma patients who progressed following prior therapies

(2018) Federico Cappuzzo et al.   Future Oncology

A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non–Small Cell Lung Cancer

(2018) Katsuyuki Hotta et al.   Journal of Thoracic Oncology

Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation–Positive Advanced NSCLC: Findings From a Global Named Patient Use Program

(2018) Solange Peters et al.   Journal of Thoracic Oncology

HER kinase inhibition in patients with HER2- and HER3-mutant cancers

(2018) David M. Hyman et al.   NATURE

HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib

(2018) Y Wang et al.   ANNALS OF ONCOLOGY

Clinical characterization of ERBB2 exon 20 insertions and heterogeneity of outcomes responding to afatinib in Chinese lung cancer patients

(2018) Zhefeng Liu et al.   OncoTargets and Therapy

Dabrafenib plus trametinib in patients with previously treated BRAF V600E -mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial

(2016) David Planchard et al.   LANCET ONCOLOGY

Outcomes of chemotherapies and HER2 directed therapies in advanced HER2-mutant lung cancers

(2016) Juliana Eng et al.   LUNG CANCER

Lung cancer patients withHER2mutations treated with chemotherapy andHER2-targeted drugs: results from the European EUHER2 cohort

(2015) J. Mazières et al.   ANNALS OF ONCOLOGY

Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors

(2015) M. G. Kris et al.   ANNALS OF ONCOLOGY

Phase I Study of Lapatinib and Pemetrexed in the Second-Line Treatment of Advanced or Metastatic Non–Small-Cell Lung Cancer With Assessment of Circulating Cell Free Thymidylate Synthase RNA as a Potential Biomarker

(2015) Rodryg Ramlau et al.   Clinical Lung Cancer

Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer

(2014) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives

(2013) Julien Mazières et al.   JOURNAL OF CLINICAL ONCOLOGY

Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer

(2013) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 (HER2) Tyrosine Kinase Mutations in Lung Adenocarcinomas

(2012) M. E. Arcila et al.   CLINICAL CANCER RESEARCH

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

(2010) Yung-Jue Bang et al.   LANCET

HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy

(2009) S. A. Perera et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA